Pictet Asset Management
APGE

Pictet Asset Management’s Apogee Therapeutics APGE Stock Holding History

Pictet Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$854K Sell
6,432
-254,618
-98% -$22.9M ﹤0.01% 1216
2026
Q1 		$22M Sell
261,050
-51,833
-17% -$3.76M 0.02% 485
2025
Q4 		$23.6M Buy
+312,883
New +$19.7M 0.02% 492

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Pictet Asset Management's APGE Position: Q2 2026 in Review

Pictet Asset Management reduced its Apogee Therapeutics (APGE) stake by 98% in Q2 2026, selling an estimated $22.9M and leaving 6,432 shares worth $854K. The position accounts for ﹤0.01% of the portfolio, ranked #1216.

Pictet Asset Management first reported a position in APGE in Q4 2025 and has held it in 3 quarters since. The position peaked at $23.6M in Q4 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Pictet Asset Management held 6,432 shares of Apogee Therapeutics worth $854K as of Q2 2026.
  • Pictet Asset Management sold 254,618 Apogee Therapeutics shares in Q2 2026, an estimated $22.9M.
  • Apogee Therapeutics made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1216 holding.
  • Pictet Asset Management first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pictet Asset Management's Apogee Therapeutics position peaked at $23.6M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.